ClinicalTrials.gg
CompletedNCT01669174Updated May 3, 2016Results posted

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

A Phase 2 interventional study of Placebo and BYM338 in Chronic Obstructive Pulmonary Disease (COPD) With Cachexia, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 3 countries. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis — none open to participants now, none under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Novartis.

Enrollment
86th of 116
67 · median 203
Started
2012
with 21 others
Phase 2
21 of 117
none open now
Registered
65th of 117
by date

Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 86th largest by enrollment of the 116 interventional ones that give a count, is one of 22 that started in 2012, is one of 21 in phase 2, and was the 65th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis as a file.
02

Study summary

This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo. The study will last for approximately 24 weeks.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD) With Cachexia

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD; cachexia; muscle wasting
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.
  • Males and females ages 40 to 80 years
  • Smoking history of at least 10 pack-years
  • Diagnosis of according to GOLD guidelines (GOLD, 2010), with a post-bronchodilator FEV¬1 \< 80% predicted and /FVC ratio \< 0.70
  • \<20 kg/m2 or skeletal muscle mass index by DXA \< 7.25 kg/m2 for men or \<5.45 kg/m2 for women.
  • In general stable health, including managed COPD, by past medical history, physical examination, vital signs at baseline as determined by the investigator.

Exclusion criteria

Exclusion criteria:

  • Patients with MRC dyspnoea grade 5 (i.e. patients too breathless to leave the house or breathless when dressing)
  • Plans for lung transplantation or lung reduction surgery within four months of enrollment
  • Patients participating in a formal pulmonary rehabilitation program within 3 months of dosing
  • History of of any organ system (other than excised non-melanomatous carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  • Diseases other than cancer known to cause cachexia or muscle atrophy, including but not limited to congestive heart failure of any stage, chronic kidney disease (estimated \< 30 mL/min using the MDRD equation), rheumatoid arthritis, primary myopathy, stroke, infection, tuberculosis or other chronic infection, uncontrolled diabetes mellitus, etc.
  • Inflammatory bowel disease, celiac disease, short bowel syndrome, pancreatic insufficiency
  • Use of any prescription drugs known to affect muscle mass, including androgen supplements, anti-androgens (such as LHRH agonists), anti-estrogens (tamoxifen, etc.) recombinant human growth hormone (rhGH), insulin, oral beta agonists, megestrol acetate, dronabinol, metformin, etc.
  • concentration below 11.0 g/dL at screening.
  • Liver disease or liver injury.
  • Use of other drugs at the time of enrollment, or within 30 days and for any other limitation of participation in an investigational trial based on local regulations.
  • Women of .

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    BYM338

    Drug: BYM338

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 4, 8, 16, and 24

    Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was no more than or equal to 2% at Week 4,8,16 and 24 was considered responders.

    Time frame: Baseline, Weeks 4, 8, 16, 24

Secondary outcomes

  1. Change in 6 Minute Walk Distance Compared to Placebo

    Practical simple test that requires a 100-ft hallway but no exercise quipment or advanced training for technicians. Walking is an activity performed daily by all but the most severely impaired patients. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD)

    Time frame: Baseline, Weeks 4, 8, 16, 24

  2. Maximum Observed Serum Concentration (Cmax)

    The observed maximum plasma concentration following drug administration

    Time frame: 0 hour, 2 hour, Day 8, 15, 29, 57, 71, 85, 99, 113, 127, 168 post dose

  3. Time to Reach the Maximum Concentration After Drug Administration (Tmax)

    The time to reach the maximum concentration after drug administration

    Time frame: 24 weeks

  4. AUC0-56 and AUClast

    AUC0-56, the area under the serum concentration-time curve from the time zero to the end of the dosing interval, day 56. AUC0-56 was analyzed for dose 1 and 2. AUClast is from time zero to the last quantifiable concentration. AUClast was analyzed for dose 2 only.

    Time frame: 0 hour, 2 hour, Day 8, 15, 29, 57, 71, 85, 99, 113, 127, 168 post dose

07

Results

Posted May 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneBYM338Placebo
Started3334
Completed2728
Not completed66
Withdrew: Subject withdrew consent22
Withdrew: Lost to follow-up10
Withdrew: Adverse event22
Withdrew: Administrative problems12

Outcome measures

PrimaryPercentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 4, 8, 16, and 24

Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was no more than or equal to 2% at Week 4,8,16 and 24 was considered responders.

Time frame:
Baseline, Weeks 4, 8, 16, 24
Reported as:
Mean · Percentage Change of TMV
Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 4, 8, 16, and 24
Percentage Change of TMVBYM338Placebo
Week 4 Day 29 (n=30,31)5.87 ± 3.4130.02 ± 3.261
Week 8 Day 57 (n=27,27)7.01 ± 3.707-0.65 ± 2.752
Week 16 Day 113 (27,28)7.84 ± 5.052-0.88 ± 4.471
End of Study, week 24 (n=27,28)5.04 ± 4.872-1.31 ± 4.282
Statistical analysis
  • BYM338 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 106.10 · 90% CI 104.64 to 107.58
  • BYM338 vs Placebo · ANCOVA · p = <0.001 · Median difference (net): 107.75 · 90% CI 106.18 to 109.35
  • BYM338 vs Placebo · ANCOVA · p = <0.001 · Median difference (net): 108.63 · 90% CI 106.31 to 111.00
  • BYM338 vs Placebo · ANCOVA · p = <0.001 · Median difference (net): 106.63 · 90% CI 104.39 to 108.93
SecondaryChange in 6 Minute Walk Distance Compared to Placebo

Practical simple test that requires a 100-ft hallway but no exercise quipment or advanced training for technicians. Walking is an activity performed daily by all but the most severely impaired patients. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD)

Time frame:
Baseline, Weeks 4, 8, 16, 24
Reported as:
Mean · meter
Change in 6 Minute Walk Distance Compared to Placebo
meterBYM338Placebo
Week 4 Day 29 (n=30,32)364.6 ± 85.45388.5 ± 100.22
Week 8 Day 57 (n=27,29)373.9 ± 101.42387.4 ± 99.73
Week 12 Day 85 (n=27,28)383.0 ± 84.63385.6 ± 107.62
Week 16 Day 113 (n=25,28)379.7 ± 83.78352.9 ± 104.01
End of Study week 24 (n=27, 28)374.9 ± 98.29378.8 ± 81.50
SecondaryMaximum Observed Serum Concentration (Cmax)

The observed maximum plasma concentration following drug administration

Time frame:
0 hour, 2 hour, Day 8, 15, 29, 57, 71, 85, 99, 113, 127, 168 post dose
Reported as:
Mean · ug/mL
Maximum Observed Serum Concentration (Cmax)
ug/mLBYM338
Cmax dose 1 (n=31)614 ± 143
Cmax dose 2 (n=26)580 ± 121
SecondaryTime to Reach the Maximum Concentration After Drug Administration (Tmax)

The time to reach the maximum concentration after drug administration

Time frame:
24 weeks
Reported as:
Median · hr
Time to Reach the Maximum Concentration After Drug Administration (Tmax)
hrBYM338
Tmax dose 1 (n=31)2.22 ± NA
Tmax dose 2 (n=26)2.23 ± NA
SecondaryAUC0-56 and AUClast

AUC0-56, the area under the serum concentration-time curve from the time zero to the end of the dosing interval, day 56. AUC0-56 was analyzed for dose 1 and 2. AUClast is from time zero to the last quantifiable concentration. AUClast was analyzed for dose 2 only.

Time frame:
0 hour, 2 hour, Day 8, 15, 29, 57, 71, 85, 99, 113, 127, 168 post dose
Reported as:
Mean · day*ug/mL
AUC0-56 and AUClast
day*ug/mLBYM338
AUC0-56 dose 1 (n=26)4540 ± 897
AUC0-56 dose 2 (n=25)5790 ± 1300
AUClast dose 2 (n=25)7480 ± 2080

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BYM338 30mg/kg—4/33 (12.1%)31/33 (93.9%)
Placebo—3/34 (8.8%)30/34 (88.2%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventBYM338 30mg/kgPlacebo
PneumoniaInfections and infestations2/331/34
Inguinal herniaGastrointestinal disorders1/330/34
Postoperative wound infectionInfections and infestations1/330/34
Cervical vertebral fractureInjury, poisoning and procedural complications1/330/34
Hip fractureInjury, poisoning and procedural complications1/330/34
Road traffic accidentInjury, poisoning and procedural complications1/330/34
Throat cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/330/34
Haemorrhage intracranialNervous system disorders1/330/34
HaematuriaRenal and urinary disorders1/330/34
Respiratory failureRespiratory, thoracic and mediastinal disorders1/330/34
Most frequent other events
Showing 10 of 60
Most frequent other events
EventBYM338 30mg/kgPlacebo
Muscle spasmsMusculoskeletal and connective tissue disorders26/3316/34
Muscle tightnessMusculoskeletal and connective tissue disorders18/335/34
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders16/3312/34
Muscle twitchingMusculoskeletal and connective tissue disorders15/339/34
Pain in extremityMusculoskeletal and connective tissue disorders8/337/34
HeadacheNervous system disorders3/338/34
DiarrhoeaGastrointestinal disorders7/333/34
MyalgiaMusculoskeletal and connective tissue disorders7/336/34
PruritusSkin and subcutaneous tissue disorders5/337/34
DyspnoeaRespiratory, thoracic and mediastinal disorders5/335/34

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BYM338PlaceboTotal
Mean64.5 ± 5.9363.1 ± 7.5163.7 ± 6.76
Sex: Female, Male
Sex: Female, Male(Participants)BYM338PlaceboTotal
Female161834
Male171633
08

Study locations

9 sites
  • Novartis Investigative Site
    Torrance, California 90502, United States
  • Novartis Investigative Site
    Savannah, Georgia 31419, United States
  • Novartis Investigative Site
    Normal, Illinois 61761, United States
  • Novartis Investigative Site
    Missoula, Montana 59808, United States
  • Novartis Investigative Site
    Spartanburg, South Carolina 29303, United States
  • Novartis Investigative Site
    Maastricht, 6211, Netherlands
  • Novartis Investigative Site
    Leicester, LE1 5WW, United Kingdom
  • Novartis Investigative Site
    London, SW 6NP, United Kingdom
  • Novartis Investigative Site
    Machester, M23 9QZ, United Kingdom
09

References and documents

Publications

  • Polkey MI, Praestgaard J, Berwick A, Franssen FME, Singh D, Steiner MC, Casaburi R, Tillmann HC, Lach-Trifilieff E, Roubenoff R, Rooks DS. Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial. Am J Respir Crit Care Med. 2019 Feb 1;199(3):313-320. doi: 10.1164/rccm.201802-0286OC. PubMed 30095981 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2012
First posted
Aug 20, 2012
Start
Sep 2012
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
May 3, 2016
Last update
May 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01669174
Responsible party
Sponsor
First posted
Aug 20, 2012
Start date
Sep 2012
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
May 3, 2016
Last update
May 3, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion